Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cytosorbents (CTSO) Debt to Equity (2016 - 2026)

Cytosorbents filings provide 9 years of Debt to Equity readings, the most recent being $2.82 for Q4 2025.

  • On a quarterly basis, Debt to Equity rose 124.07% to $2.82 in Q4 2025 year-over-year; TTM through Dec 2025 was $2.82, a 124.07% increase, with the full-year FY2025 number at $2.82, up 124.07% from a year prior.
  • Debt to Equity hit $2.82 in Q4 2025 for Cytosorbents, up from $1.61 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $2.82 in Q4 2025 to a low of $0.14 in Q4 2022.
  • Median Debt to Equity over the past 4 years was $0.88 (2024), compared with a mean of $0.9.
  • Biggest five-year swings in Debt to Equity: skyrocketed 51.95% in 2023 and later soared 486.72% in 2024.
  • Cytosorbents' Debt to Equity stood at $0.14 in 2022, then soared by 51.95% to $0.21 in 2023, then soared by 486.72% to $1.26 in 2024, then skyrocketed by 124.07% to $2.82 in 2025.
  • The last three reported values for Debt to Equity were $2.82 (Q4 2025), $1.61 (Q3 2025), and $1.24 (Q2 2025) per Business Quant data.